Hurrah for New and News

Brain cancer is...

 ...enjoying new and news.

Today we appreciate my new, post-Mousse glasses and Darrell's new, non-black bucket hat.

We also appreciate the news that some Team D members have shared with us:  The results of the next phase of an Optune study were released this month. 

Recall that the FDA halted the Phase 3 Optune study in October of 2015 because the results clearly favored the treatment group (surgery, radiation, and chemotherapy, plus Optune users) above the control group (surgery, radiation, and chemotherapy only users) for newly diagnosed Glioblastoma. 

Newest results suggest that Optune prolongs life for the average GBM patient by 5 months.  It increases two-year survival rates to 43%.  Optune nearly triples five-year survival rates (still low--13% compared to 5%, but still:  Nearly triple! And we're talking Big D!). 

Brenda sent the early, technical version of results, which were carried on OncLive.

Here's the Internet version of the EyeWitness News clip from last week that Gordon shared with us.
 
Here's the Slowiks' offering of the New York Times write up.  

And here it is in the Washington Times.

Hurrah for science! Hooray for innovation! Hurrah for Team D members! Hurrah for hats!